Introduction {#sec1-1}
============

It has been reported that one of six men and one of five women (55-75 years old) will suffer from stroke sometime during their lives. Three phases have been described in stroke: excitotoxicity, inflammatory activation/apoptosis and regeneration.^[@ref1]^ In stroke, an activation of caspases, cytokines and both nitric oxide (NO) and indoleamine 2, 3-dioxygenase (IDO) pathways occurs. In the latter pathway, nicotinamide adenine dinucleotide (NAD) and several intermediate metabolites *(e.g.*, 3-OH-anthranilic acid -- 3-HAA) are generated. It is known that, at pathophysiological concentrations, some of these intermediate metabolites *(e.g.*, 3-HAA) exert a cytotoxic effect^[@ref2]^ and that, in the cerebrospinal fluid of patients suffering from Huntington's disease, the level of 3-HAA is increased.^[@ref2],[@ref5]^ Thus, for example, it has been reported that 3-HAA generates hydrogen peroxide and superoxide promoting oxidative protein damage, induces apoptosis, and inhibits the mitochondrial respiratory chain.^[@ref3],[@ref6]^ Moreover, 3-HAA has been involved in the initiation, development and amplification of neurodegenerative processes.^[@ref12]^ However, the distribution of immunoreactive structures containing 3-HAA in the mammalian central nervous system is currently unknown (in both normal and pathological conditions). In order to develop new strategies for the treatment of several pathologies *(e.g.*, stroke, Huntington's disease), immunohistochemical studies should be carried out to know the distribution of immunoreactive structures containing 3-HAA in the mammalian brain.

In light of the above, our first aim in this study was to develop a highly specific monoclonal antibody directed against 3-HAA, and the second to know the distribution of the immunoreactive structures containing 3-HAA in the brain of normal rats and in animals in which a stroke model (single transient middle cerebral artery occlusion) was induced.

Materials and Methods {#sec1-2}
=====================

Single transient middle cerebral artery occlusion (tMCAO) {#sec2-1}
---------------------------------------------------------

This study was approved by the research commission of the University of Salamanca (Spain). The experimental procedure of this work was performed under the guidelines of the legal and ethics recommendations of French, Spanish and European laws. Eighteen adult male Wistar rats (350 g) were used. Animals were deeply anesthetized with isoflurane and, as previously described, the tMCAO chirurgical procedure was performed:^[@ref13]^ using a rounded tip monofilament (Doccol Co., Sharon, MA, USA), a single transient middle artery cerebral occlusion was carried out for 50 min. tMCAO rats were divided into three groups: 2D, 5D and 21D. That is, animals were perfused two (2D), five (5D) or twenty-one (21D) days after the middle artery cerebral occlusion. In each experimental group, 6 animals were used: four tMCAO animals and two control rats.

Antibody development {#sec2-2}
--------------------

As previously described,^[@ref16]^ a primary antiserum was developed in BALB/c mice after immunization with 3-HAA-bovine serum albumin (BSA) immunogen linked *via* ethylchloroformiate (ECF). Thus, 20 mg of BSA were dissolved in water, whereas 10 mg of 3-HAA were dissolved in methanol; later, 40 μL of triethylamine were added to both solutions. Then, 375 μL of dimethylformamide mixed with 25 μL of ECF was added in order to activate the 3-HAA solution. After 10 min of activation, the 3-HAA solution was added into a tube containing the BSA solution. Using dialysis membranes (with cut-off limits between 12 and 16 KDa), the obtained conjugate (3-HAA-BSA) was purified by dialysis. Later, the purification was carried out as previously described.^[@ref16]^

Once the 3-HAA-BSA was synthesized, mice were immunized with the immunogen (containing 3-HAA-BSA). Each immunization was carried out by administering 50 μL of an immunogenic NaCl solution and 50 μL of complete (only used in the first immunization) or incomplete Freund adjuvant. As previously described,^[@ref16]^ serum samples were collected and the antisera were pre-purified by immunoabsorption and tested by ELISA. Once a highly specific polyclonal antibody was obtained, the fusion of SP2/O/Ag myeloma cells and mice splenocytes was performed and the screening and the selection of specific clones were carried out. Once the highly specific monoclonal antibody against 3-HAA was obtained, cells were expanded in plastic flasks. Supernatant was collected every week, centrifuged and pre-purified with a saturated (NH~4~)~2~SO~4~ solution, dialyzed in PBS and purified in an HiTrap protein G HP column (17-0404-01, GE Healthcare, Little Chalfont, UK). An Isotyping kit was used to determinate the type of immunoglobulin and chain (26179, ThermoScientific, Waltham, MA, USA): the anti-3-HAA antibody was characterized as an isotype Ig G~1~ and κ chain. The affinity estimated of the monoclonal anti-3-HAA antibody was 10^-9^ M and its specificity was considered excellent because close molecules were not recognized by the antibody ([Table 1](#table001){ref-type="table"}).

Immunohistochemical study {#sec2-3}
-------------------------

Once the tMCAO model was carried out (2, 5 or 21 days), the immunocytochemical study was performed. As previously reported,^[@ref16],[@ref17]^ animals were anaesthetized with isoflurane (4% induction, 2.5% maintenance) and perfused (4% paraformaldehyde); the brains were dissected out, post-fixed in paraformaldehyde (4%) (15-18 h) and cryoprotected in increasing sucrose baths (5-30%) (5-7 days). Using a freezing microtome, 40 μ-thick brain sections were obtained and processed for immunohistochemistry. Sections were treated with H~2~O~2~ (10 mL) and methanol (20 mL) for 30 min to avoid possible interference by endogenous peroxidase. Then, sections were washed in PBS (30 min) and pre-incubated (30 min) in the mix solution (PBS containing 0.3% Triton X-100 and 1% normal horse serum). Later, sections were incubated overnight at 4° C in the mix solution containing the monoclonal anti- 3-HAA antibody (diluted 1/1,000, Gemacbio, Saint-Jean-d'Illac, France), the polyclonal goat anti-ionized calcium-binding adapter molecule 1 (IBA-1) antibody (1/1,500, Abcam), the polyclonal rabbit anti-glial fibrillary acidic protein (GFAP) antibody (1/100, Dako, Glostrup, Denmark) or the monoclonal anti-GFAP antibody (1/400, Abcam, Cambridge, UK). Sections were washed in PBS (30 min) and incubated at room temperature for 1 h with biotinylated anti-mouse/rabbit/goat immunogammaglobulin (BA-1,000; BA-9,200; BA-5,000, Vector Labs, Burlingame, CA, USA), diluted 1/200 in the mix solution. After a rinse in PBS (30 min), sections were incubated (room temperature, 1 h) with the avidin-biotin-peroxidase complex (ABC, Vectastain PK-6,100) (1/100) and were washed in PBS (30 min) and Tris-HCl buffer (15 min). Finally, the tissue-bound peroxidase was developed with H~2~O~2~, using 3, 3' diaminobenzidine as chromogen (5-10 min). Histological controls were carried out to confirm the specificity of the immunoreactivity: i) pre-absorption of the anti-3-HAA antibody with an excess (100 g/mL) of 3-HAA; ii) omission of the primary and/or secondary antibodies. No residual immunoreactivity was found in either case.

According to a previous published protocol,^[@ref19]^ 3-HAA immunoreactive sections (3-HAA was detected by the DAB developing procedure) were prepared for double-labelling immunohistochemistry (GFAP: 1/100, Dako). The chromogen 4-chloro-1-naphthol was used to reveal the second immunohistochemical reaction (GFAP). The brown product (3-HAA) of DAB is easily distinguishable from the 4-chloro-1-naphthol which provides a blue precipitate (GFAP).^[@ref19]^ The DAB reaction product masks the antigen and catalytic sites of the first sequence of immunoreagents, preventing an interaction of the second sequence with the reagents.^[@ref20]^

The stereotaxic atlas of Paxinos and Watson^[@ref21]^ was used for mapping and nomenclature. Photomicrographs were obtained with an Olympus DP50 digital camera attached to a Kyowa Unilux-12 microscope. Using a Leica DMRB photomicroscope/Neurolucida system (8.0; Microbrightfield-bioscience, Williston, VT, USA) photographs at low-power magnification were also obtained. To improve the visualization of results, only the brightness and contrast of the images were adjusted. Adobe Photoshop Elements software was used.

Results {#sec1-3}
=======

The monoclonal anti-3-HAA antibody used here was fully characterized by ELISA ([Table 1](#table001){ref-type="table"}). This antibody showed an excellent specificity and a high affinity (the IC~50~ was 10^-9^ M). According to protocols previously described,^[@ref16],[@ref17]^ the parameters studied in these assays were antibody titration, avidity and specificity versus other close structural analogues ([Table 1](#table001){ref-type="table"}). Competition experiments were carried out with different competitors ([Table 1](#table001){ref-type="table"}); these experiments were performed with the same amount of antibody (dilution: 1/30,000), but using different concentrations of the conjugated antigens *(e.g.*, anthranilic acid) ([Table 1](#table001){ref-type="table"}). As previously reported,^[@ref17]^ ELISA tests were performed with the dilution of 1/30,000, corresponding to an optical density of 1, at 492 nm. The anti-3-HAA monoclonal antibody used in this study recognized, at very low concentrations, the specific target; this means that its avidity was very high for 3-HAA.^[@ref17],[@ref18],[@ref22]^ No cross-reactivity between the target molecule (3-HAA) and the closest analogues of 3-HAA was observed ([Table 1](#table001){ref-type="table"}).

In this study, three markers have been used: IBA-1 (to check that the tMCAO model was well performed; immunoreactivity was observed in microglia) ([Figures 1A](#fig001){ref-type="fig"}, [2 A, B](#fig002){ref-type="fig"} and [3A](#fig003){ref-type="fig"}), GFAP (to show astrocytes) ([Figure 2 C, D](#fig002){ref-type="fig"}) and 3-HAA ([Figures 1B](#fig001){ref-type="fig"}, [2 E, F](#fig002){ref-type="fig"} and [3 B-F](#fig003){ref-type="fig"}). 3-HAA was exclusively found in the infarcted regions ([Figures 1B](#fig001){ref-type="fig"}, [2 E, F](#fig002){ref-type="fig"} and [3 B, C, E, F](#fig003){ref-type="fig"}); that is, in the ipsilateral side (striatum and/or cerebral cortex) of animals in which the tMCAO model was carried out. The distribution of 3-HAA perfectly matches with the infarcted region ([Figures 1B](#fig001){ref-type="fig"} and [3B](#fig003){ref-type="fig"}). In this region, 3-HAA was observed in astrocytes, since cells containing 3-HAA or GFAP showed the same morphological characteristics ([Figures 2 C-F](#fig002){ref-type="fig"} and [3 C, E, F](#fig003){ref-type="fig"}). In order to confirm this morphological observation, the coexistence of GFAP and 3-HAA was demonstrated by using a double-labelling immunohistochemistry technique: GFAP-immunoreactivity was observed in those astrocytes expressing 3-HAA ([Figure 4 A-F](#fig004){ref-type="fig"}). In control animals, in the contralateral side of the tMCAO animals and in the non-infarcted region of the ipsilateral side, 3-HAA was not observed ([Figures 1B](#fig001){ref-type="fig"} and [3D](#fig003){ref-type="fig"}), but as expected in these animals/areas microglia containing IBA-1 and GFAP-immunoreactive astrocytes were found. In the three experimental groups studied (2D, 5D, 21D), all the findings mentioned above, were similar.

Discussion {#sec1-4}
==========

We have demonstrated here, for the first time, the presence of 3-HAA (under pathological conditions) in the mammalian brain. In stroke, the expression of 3-HAA occurs from early stages and it is exclusively observed in the infarcted regions: there is a perfect anatomical relationship between the expression of 3-HAA and the infarcted region.

Regarding the development of the monoclonal anti-3-HAA antibody used here, it is very important during the process to maintain the original chemical structure/spatial conformation of the target.^[@ref17],[@ref18]^ In this study, 3-HAA and the competitors used *(e.g.*, anthranilic acid) were linked to BSA via different coupling agents *(e.g.*, glutaraldehyde, ECF). To confirm that the original chemical structure of both target (3-HAA) and competitors was not modified by the linkage procedure, competition ELISA tests were carried out. These tests confirmed that the monoclonal anti-3-HAA antibody recognized specifically 3-HAA, independently of the linkage procedure followed.^[@ref18]^ Moreover, the monoclonal antibody did not

recognize any competitor. The procedure previously described is crucial for later studies (immunohistochemistry, Western-blotting) in order to recognize specifically the desired target and to avoid unspecific labelling (background). Due to the high affinity (10^-9^ M) and specificity of the monoclonal anti-3-HAA antibody used here, we have visualized for the first time the presence of 3-HAA in mammalian astrocytes. Moreover, the specificity of the immunoreactivity was confirmed when several histological controls *(e.g.*, omission of the first antibody) were carried out.

In the tMCAO model, a considerable variability in the extension of the infarcted region has been reported.^[@ref23]^ It is also known that IBA-1 is specifically expressed in microglia and is up-regulated following cerebral ischemia.^[@ref24]^ Here, in tMCAO animals, the up-regulation of IBA-1 was observed in the infarcted regions (striatum and/or cerebral cortex) and hence, in some animals, the location and/or extension of the infarcted regions were different. Since astrocytes containing 3-HAA were exclusively observed in the infarcted regions, the location and/or extension of the regions showing 3-HAA-immunoreactive structures (striatum and/or cerebral cortex) were different in some tMCAO animals. In sum, our data are agreement with the observations previously reported in the tMCAO experimental model,^[@ref23],[@ref24]^ confirming that the chirurgical procedure (tMCAO) was correctly carried out.

We have demonstrated the coexistence of 3-HAA and GFAP in astrocytes. This was exclusively observed in those astrocytes located in the infarcted region. In our study, two different anti-GFAP antibodies were used and, in both cases, the results were identical. It is important to note that the expression of 3-HAA was observed in the three experimental groups studied (2D, 5D, 21D); this means that, in stroke, 3-HAA was expressed from early stages and that this expression continued 21 days post-stroke.

In the IDO pathway, several important processes occur: tryptophan is catabolised and intermediate metabolites *(e.g.*, 3-HAA, kynurenine, quinolinic acid, kynurenic acid) and NAD are generated. This pathway regulates the immune response *(e.g.*, 3-HAA controls the population of Th 17 lymphocytes)^[@ref25]^ and is altered in several pathologies *(e.g.*, stroke, Alzheimer's disease, amyotrophic lateral sclerosis, depression, Huntington's disease, multiple sclerosis, Parkinson's disease, schizophrenia).^[@ref3],[@ref6],[@ref28],[@ref29]^ It is known that the metabolites generated in the IDO pathway exert opposite effects: kynurenic acid has a neuroprotective action, whereas 3-HAA (a free radical generator), quinolinic, and picolinic acids exert a cytotoxic effect.^[@ref6],[@ref29]^ In the case of 3-HAA, it is well known that this intermediate metabolite and precursor of quinolinic impairs brain energy metabolism, generates hydrogen peroxide and superoxide promoting oxidative protein damage and induces apoptosis.^[@ref3],[@ref6]^ It has been also reported that a neurotoxic effect was observed when the concentration of 3-HAA was \>100 nM, but a lower concentration increased the level of NAD+, exerting a beneficial effect on cultured human neurons and astrocytes.^[@ref2],[@ref34]^ The former is in agreement with our anatomical results in which an overexpression of 3-HAA (observed from early stages in stroke) was exclusively found in the infarcted regions. Moreover, in stroke, a down-regulation of the expression of 3-HAA has been observed (personal communication, unpublished data) after the administration of new drug candidates exerting anti-oxidative and anti-inflammatory effects.^[@ref35]^ Thus, 3-HAA immunoreactivity was modulated by these drugs. This preliminary finding is in agreement with published data reporting that inflammatory mediators *(e.g.*, lipopolysaccharide, interleukin-1) stimulates the kynureninase enzyme to produce 3-HAA.^[@ref36]^ According to the above mentioned data, it seems that in the tMCAO model, the ipsilateral overexpression of 3-HAA is involved in the tissue damage observed in the infarcted regions. However, this must be confirmed in future studies. 3-HAA is expressed from early stages in stroke and hence, in the future, strategies against the overexpression of 3-HAA (once its cytotoxic action was fully demonstrated) should be developed. It is known that two enzymes (microsomal hydroxylase, kynureninase) are involved in the synthesis of 3-HAA^[@ref37]^ and, according to our anatomical results, it seems that they could be up-regulated in astrocytes under ischemic conditions. Under these conditions, an increase in the level of 3-HAA will produce an increase in the level of quinolinic acid (this intermediate metabolite of the IDO pathway exerts the highest cytotoxic effect).^[@ref12],[@ref38]^ Accordingly, it has been reported that quinolinic acid favored neuronal/glial damage and/or death by at least nine different processes and that inhibitors of the 3-HAA oxidase (involved in the synthesis of quinolinic acid from 3-HAA) reduced quinolinic acid accumulation and deficits caused.^[@ref7],[@ref12],34,[@ref38]^

In conclusion, in a tMCAO stroke model, i) for the first time, 3-HAA has been observed in the astrocytes of mammals; ii) 3-HAA was exclusively found in the infarcted regions; in control animals, 3-HAA-immunoreactive structures were not visualized; iii) from early stages, an overexpression of 3-HAA has been observed; iv) an anatomical relationship between the expression of 3-HAA and the infarcted region occurred; and v) 3-HAA, acting as a possible cytotoxic factor, could be involved in the tissue damage observed in the infarcted regions.
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![Low-power magnification (cerebral cortex: 21 days). Photographs were taken using a Leica microscope/ Neurolucida software. A) Section stained with IBA-1, a pan-microglia marker. B) Section stained with 3-HAA. Arrowheads indicate the infarcted region.](ejh-2016-4-2709-g001){#fig001}

![A) Infarcted region (ipsilateral side; cerebral cortex: 21 days) stained with anti-IBA-1. B) Infarcted region; microglia containing IBA-1. C) Infarcted region; coronal contiguous section to that shown in [Figure 1A. D](#fig001){ref-type="fig"}) Higher-power magnification of the rectangle showed in [Figure 1C](#fig001){ref-type="fig"}; GFAP-immunoreactive astrocytes. E) Infarcted region; coronal contiguous section to that shown in [Figure 1C](#fig001){ref-type="fig"}; 3-HAA is observed in astrocytes. F) Higher-power magnification of the region delimited by a rectangle in [Figure 1E](#fig001){ref-type="fig"}. L, lateral; V, ventral.](ejh-2016-4-2709-g002){#fig002}

![Infarcted region (ipsilateral side; cerebral cortex: 21 days) stained with anti-IBA-1 (A) or anti-3-HAA (B). Photographs in [Figure 2A](#fig002){ref-type="fig"} and [B](#fig002){ref-type="fig"} were taken from contiguous sections. The border of the infarcted region is clearly observed in [Figure 2B](#fig002){ref-type="fig"}. 3-HAAimmunoreactive astrocytes are exclusively found in the infarcted region. C) Higher-power magnification of the region delimited by a rectangle in [Figure 2B. D](#fig002){ref-type="fig"}). Contralateral cerebral cortex of the same section shown in [Figure 2B](#fig002){ref-type="fig"}; note the absence of immunoreactivity for 3-HAA. E, F) High-power magnification of the infarcted region; 3-HAA-immunoreactive astrocytes can be observed. L, lateral; M, medial; V, ventral.](ejh-2016-4-2709-g003){#fig003}

![Infarcted region (ipsilateral side; cerebral cortex: 21 days); double-labeling immunohistochemistry. In astrocytes, the coexistence of GFAP (blue labelling, arrowheads) and 3-HAA (brown labelling) is observed.](ejh-2016-4-2709-g004){#fig004}

###### 

Affinity and specificity of antibodies against conjugated 3-HAA.

  Compounds                        Cross-reactivity at half-displacement (IC~50~)
  -------------------------------- ------------------------------------------------
  3-hydroxy-anthranilic acid-BSA   1
  Anthranilic acid-BSA             1/\>50,000
  Free anthranilic acid            1/\>50,000
  Xanthurenic acid-BSA             1/\>50,000
  Picolinic acid-BSA               1/\>50,000

Using competition ELISA tests, cross-reactivity was calculated from the displacement curves at half-displacement: the best recognized conjugate was 3-HAA-BSA, whose concentration was divided by the concentration of each of the other conjugates
